Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells

International Journal of Cancer

Volumn 130, Issue 3, 2012, Pages 532-543

  Liby, Tiera A ^a,d   Spyropoulos, Perry ^a   Buff Lindner, Haley ^a   Eldridge, Juanita ^a   Beeson, Craig ^b   Hsu, Tien ^c   Muise Helmericks, Robin C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; AKT3 PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN KINASE B; RCAS1 PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENDOPLASMIC RETICULUM; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE SILENCING; GOLGI COMPLEX; MITOCHONDRIAL GENE; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; XENOGRAFT;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; MICE, SCID; MITOCHONDRIA; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82255186529     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26010     Document Type: Article

References (37)

1. Bamberger ES, Perrett CW,. Angiogenesis in epithelian ovarian cancer. Mol Pathol 2002; 55: 348-59. (Pubitemid 35454510)
2. Kumaran GC, Jayson GC, Clamp AR,. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1-7.
3. Berra E, Milanini J, Richard DE, Le Gall M, Vinals F, Gothie E, Roux D, Pages G, Pouyssegur J,. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem Pharmacol 2000; 60: 1171-8.
4. Pages G, Milanini J, Richard DE, Berra E, Gothie E, Vinals F, Pouyssegur J,. Signaling angiogenesis via p42/p44 MAP kinase cascade. Ann N Y Acad Sci 2000; 902: 187-200. (Pubitemid 30389123)
5. Semenza GL, Agani F, Feldser D, Iyer N, Kotch L, Laughner E, Yu A,. Hypoxia, HIF-1, and the pathophysiology of common human diseases. Adv Exp Med Biol 2000; 475: 123-30. (Pubitemid 32197719)
6. Chen H, Ye D, Xie X, Chen B, Lu W,. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004; 94: 630-5. (Pubitemid 39194453)
7. Han ES, Lin P, Wakabayashi M,. Current status on biologic therapies in the treatment of epithelial ovarian cancer. Current treatment options in oncology 2009.
8. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW,. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102. (Pubitemid 29036292)
9. Cristiano BE, Chan JC, Hannan KM, Lundie NA, Marmy-Conus NJ, Campbell IG, Phillips WA, Robbie M, Hannan RD, Pearson RB,. A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. Cancer Res 2006; 66: 11718-25. (Pubitemid 46094184)
10. Marte BM, Downward J,. PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 1997; 22: 355-8.
11. Bos JL,. A target for phosphoinositide 3-kinase: Akt/PKB. Trends Biochem Sci 1995; 20: 441-2.
12. Maroulakou IG, Oemler W, Naber SP, Tsichlis PN,. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 2007; 67: 167-77. (Pubitemid 46142772)
13. Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP, Testa JR,. Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002; 87: 470-6.
14. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR,. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A 1996; 93: 3636-41. (Pubitemid 26127592)
15. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, Chung DH, Evers BM,. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A 2008; 105: 20315-20.
16. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB,. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008; 99: 1265-8.
17. Sandau KB, Faus HG, Brune B,. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000; 278: 263-7.
18. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ,. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood 1997; 90: 3322-31. (Pubitemid 27473400)
19. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM,. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
20. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC,. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-9. (Pubitemid 28022851)
21. Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS, Lee VM, Szabolcs M, de Jong R, Oltersdorf T, Ludwig T, Efstratiadis A, et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 2005; 25: 1869-78. (Pubitemid 40280150)
22. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T, Michaelis T, Frahm J, Hemmings BA,. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 2005; 132: 2943-54. (Pubitemid 41086730)
23. Wright GL, Maroulakou IG, Eldridge J, Liby TL, Sridharan V, Tsichlis PN, Muise-Helmericks RC,. VEGF stimulation of mitochondrial biogenesis: requirement of AKT3 kinase. Faseb J 2008.
24. Bonifacino JS,. Current protocols in cell biologyed. New York: John Wiley, 2001.
25. Sonoda K, Miyamoto S, Yamazaki A, Kobayashi H, Nakashima M, Mekada E, Wake N,. Biologic significance of receptor-binding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer 2007; 110: 1979-90. (Pubitemid 350036857)
26. Reimer TA, Anagnostopoulos I, Erdmann B, Lehmann I, Stein H, Daniel P, Dorken B, Rehm A,. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker. BMC Cancer 2005; 5: 47.
27. Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006; 66: 1181-90. (Pubitemid 43165989)
28. Rousseau J, Tetu B, Caron D, Malenfant P, Cattaruzzi P, Audette M, Doillon C, Tremblay JP, Guerette B,. RCAS1 is associated with ductal breast cancer progression. Biochem Biophys Res Commun 2002; 293: 1544-9. (Pubitemid 34681054)
29. Noguchi K, Enjoji M, Nakamuta M, Nakashima M, Nishi H, Choi I, Taguchi K, Kotoh K, Shimada M, Sugimachi K, Tsuneyoshi M, Nawata H, et al. Expression of a tumor-associated antigen RCAS1 in hepatocellular carcinoma. Cancer Lett 2001; 168: 197-202. (Pubitemid 32524282)
30. Akahira JI, Aoki M, Suzuki T, Moriya T, Niikura H, Ito K, Inoue S, Okamura K, Sasano H, Yaegashi N,. Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer. Br J Cancer 2004; 90: 2197-202. (Pubitemid 38869730)
31. Nakashima M, Sonoda K, Watanabe T,. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med 1999; 5: 938-42. (Pubitemid 29372422)
32. Engelsberg A, Hermosilla R, Karsten U, Schulein R, Dorken B, Rehm A,. The Golgi protein RCAS1 controls cell surface expression of tumor-associated O-linked glycan antigens. J Biol Chem 2003; 278: 22998-3007. (Pubitemid 36830365)
33. Ruder C, Reimer T, Delgado-Martinez I, Hermosilla R, Engelsberg A, Nehring R, Dorken B, Rehm A,. EBAG9 adds a new layer of control on large dense-core vesicle exocytosis via interaction with Snapin. Mol Biol Cell 2005; 16: 1245-57. (Pubitemid 40349561)
34. Fieber CB, Eldridge J, Taha TA, Obeid LM, Muise-Helmericks RC,. Modulation of total Akt kinase by increased expression of a single isoform: Requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells. Exp Cell Res 2006; 312: 1164-73.
35. Lee HC, Wei YH,. Mitochondrial DNA instability and metabolic shift in human cancers. Int J Mol Sci 2009; 10: 674-701.
36. Nadege B, Patrick L, Rodrigue R,. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009; 14: 4015-34.
37. Santos C, Martinez M, Lima M, Hao YJ, Simoes N, Montiel R,. Mitochondrial DNA mutations in cancer: a review. Curr Top Med Chem 2008; 8: 1351-66.